Eris Lifesciences (ERIS) Q4 22/23 earnings summary

Executive summary

• FY23 consolidated operating revenue rose 25.1% to ₹16,851 mn; EBITDA was ₹5,367 mn and PAT ₹3,742 mn, with acquisition-led diversification offset by lower margins and earnings.

• Three dermatology acquisitions totaling ₹12,650 mn expanded the portfolio; emerging therapies reached 26% of revenue from 12% in FY22.

Financial highlights

• Consolidated revenue grew 25.1% YoY to ₹16,851 mn; excluding Covid products and at-risk launches, growth was 31%.

• Consolidated EBITDA increased 10.7% to ₹5,367 mn; EBITDA margin declined to 31.9% from 36.0%, while EBIT was nearly flat at ₹4,197 mn.

• Consolidated PAT fell 7.8% to ₹3,742 mn; PAT margin was 22.2% and EPS ₹28.10 versus ₹29.89 in FY22.

• Standalone revenue grew 9.5% to ₹13,307 mn; excluding Covid products and at-risk launches, growth was 15.6%. Standalone PAT declined 4.6% to ₹3,980 mn.

• Consolidated gross margin was 79.1%, down 172 bps YoY; standalone gross margin was 82.2%, down 134 bps, recovering to 84.5% in Q4 FY23.

Outlook and guidance

• Consolidated gross and EBITDA margins are expected to improve from FY24 as Oaknet expands margins, insulin losses narrow, new products scale and Gujarat insourcing benefits accrue.

• Insulin venture losses are expected to narrow in FY24, with profitability targeted from FY25; Liraglutide and other insulin analogues are in the pipeline.

• Significant debt prepayment is targeted in FY24; Gujarat plant benefits and first-in-market FDC launches are expected from FY24 onward.

• Growth priorities include power-brand expansion, new products, broader physician coverage and selective M&A; management expects to outperform in core therapies.